NeuroBo Pharmaceuticals Stock Price, News & Analysis (NASDAQ:NRBO) $0.51 +0.01 (+2.76%) (As of 01:19 PM ET) Add Compare Share Share Today's Range$0.49▼$0.5250-Day Range$0.41▼$0.4952-Week Range$0.36▼$2.33Volume61,222 shsAverage Volume438,972 shsMarket Capitalization$19.62 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media About NeuroBo Pharmaceuticals Stock (NASDAQ:NRBO)NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.Read More NRBO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NRBO Stock News HeadlinesDecember 1, 2023 | finance.yahoo.comNeuroBo to Participate in Investor Conferences in DecemberNovember 14, 2023 | finanznachrichten.deNeuroBo Pharmaceuticals, Inc.: NeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateDecember 6, 2023 | Edge On The Street (Ad)Henry Ford Would NEVER Have Seen This ComingIn 1908, Henry Ford used a metal called vanadium in his Model T cars. Over a century later, automakers still turn to vanadium to make car bodies lighter and stronger. Today, this under-appreciated metal plays the starring role in cutting-edge battery tech set to revolutionize the energy storage market.November 13, 2023 | msn.comNeuroBo Pharmaceuticals GAAP EPS of -$0.09 beats by $0.02November 13, 2023 | finance.yahoo.comNeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 6, 2023 | finance.yahoo.comNeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi, M.D.October 17, 2023 | finance.yahoo.comNeuroBo to Present at the H.C. Wainwright 7th Annual NASH Investor ConferenceSeptember 15, 2023 | finance.yahoo.comNeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASHDecember 6, 2023 | Edge On The Street (Ad)Henry Ford Would NEVER Have Seen This ComingIn 1908, Henry Ford used a metal called vanadium in his Model T cars. Over a century later, automakers still turn to vanadium to make car bodies lighter and stronger. Today, this under-appreciated metal plays the starring role in cutting-edge battery tech set to revolutionize the energy storage market.August 16, 2023 | finanznachrichten.deNeuroBo Pharmaceuticals, Inc.: NeuroBo Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 14, 2023 | markets.businessinsider.comNeuroBo Appoints Hyung Heon Kim As CEOAugust 14, 2023 | finance.yahoo.comNEUROBO PHARMACEUTICALS APPOINTS HYUNG HEON KIM AS CHIEF EXECUTIVE OFFICER AND PRESIDENTAugust 9, 2023 | finance.yahoo.comNeuroBo Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 3, 2023 | finance.yahoo.comNeuroBo Pharmaceuticals Receives First Site IRB Approval for its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASHAugust 2, 2023 | finance.yahoo.comNeuroBo Pharmaceuticals Enters Into Term Sheet With MThera Pharma to Out-license NB-01June 27, 2023 | msn.comNeuroBo Pharma Says Its Weight Loss Candidate Outperforms Major Competitors in Preclinical Obesity StudyJune 27, 2023 | finance.yahoo.comNeuroBo Pharmaceuticals' Novel GLP1R and GCGR Dual Agonist, DA-1726, Shown to Elicit Superior Weight Loss Efficacy Compared to Semaglutide and Tirzepatide in Preclinical ModelsJune 24, 2023 | fool.comNeuroBo Pharmaceuticals (NASDAQ: NRBO)June 13, 2023 | finance.yahoo.comNeuroBo Pharmaceuticals Announces Acceptance of Two General Posters and One ePoster Theater Discussion of its Novel GLP1R and GCGR Dual Agonist, DA-1726, at the American Diabetes Association 83rd Scientific SessionsJune 13, 2023 | forbes.comTeva Pharmaceutical IndsJune 6, 2023 | finance.yahoo.comHere's Why NeuroBo Pharmaceuticals, Inc. (NRBO) Could be Great Choice for a Bottom FisherMay 12, 2023 | finance.yahoo.comNeuroBo Pharmaceuticals, Inc. Appoints Pharmaceutical Industry Executive, Mark A. Glickman, to its Board of DirectorsMay 2, 2023 | finance.yahoo.comNeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 2a Clinical Trial of DA-1241 for the Treatment of NASHApril 3, 2023 | finance.yahoo.comNeuroBo Pharmaceuticals Announces Submission of IND Application to the FDA for a Phase 2a Clinical Trial of DA-1241 for the Treatment of NASHMarch 31, 2023 | finanznachrichten.deNeuroBo Pharmaceuticals, Inc.: NeuroBo Pharmaceuticals Reports Full Year 2022 Financial ResultsMarch 30, 2023 | finance.yahoo.comNeuroBo Pharmaceuticals Reports Full Year 2022 Financial ResultsJanuary 18, 2023 | marketwatch.comNeuroBo Pharmaceuticals President, CEO Gil Price Resigns >NRBOSee More Headlines Receive NRBO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuroBo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today12/06/2023Fiscal Year End12/31/2023Next Earnings (Estimated)4/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NRBO CUSIPN/A CIK1638287 Webwww.neurobopharma.com Phone(857) 702-9600Fax734-293-0444Employees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,970,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-53.17% Return on Assets-39.24% Debt Debt-to-Equity RatioN/A Current Ratio5.54 Quick Ratio5.54 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.86 per share Price / Book0.57Miscellaneous Outstanding Shares38,810,000Free Float38,506,000Market Cap$19.09 million OptionableNot Optionable Beta-0.11 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Hyung-Heon Kim (Age 48)CEO, President, Principal Executive & Director Comp: $54.22kMr. Marshall H. Woodworth (Age 65)Acting CFO, Principal Financial Officer & Principal Accounting Officer Dr. Mi-Kyung KimChief Scientific OfficerMr. Robert HomolkaSenior Vice President of Clinical OperationsKey CompetitorsMainz BiomedNASDAQ:MYNZAkari TherapeuticsNASDAQ:AKTXCalciMedicaNASDAQ:CALCRedHill BiopharmaNASDAQ:RDHLPieris PharmaceuticalsNASDAQ:PIRSView All Competitors NRBO Stock Analysis - Frequently Asked Questions Should I buy or sell NeuroBo Pharmaceuticals stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NeuroBo Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NRBO shares. View NRBO analyst ratings or view top-rated stocks. How have NRBO shares performed in 2023? NeuroBo Pharmaceuticals' stock was trading at $0.7175 at the beginning of the year. Since then, NRBO stock has decreased by 27.5% and is now trading at $0.52. View the best growth stocks for 2023 here. When is NeuroBo Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our NRBO earnings forecast. How were NeuroBo Pharmaceuticals' earnings last quarter? NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) posted its quarterly earnings data on Monday, November, 13th. The company reported ($0.09) earnings per share for the quarter. When did NeuroBo Pharmaceuticals' stock split? NeuroBo Pharmaceuticals shares reverse split before market open on Tuesday, September 13th 2022. The 1-30 reverse split was announced on Tuesday, September 13th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 13th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of NeuroBo Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other NeuroBo Pharmaceuticals investors own include Fulcrum Therapeutics (FULC), Cumberland Pharmaceuticals (CPIX), Akero Therapeutics (AKRO), Chimerix (CMRX), Trevena (TRVN), VBI Vaccines (VBIV), VIVUS (VVUS) and Aldeyra Therapeutics (ALDX). Who are NeuroBo Pharmaceuticals' major shareholders? NeuroBo Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of NeuroBo Pharmaceuticals? Shares of NRBO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:NRBO) was last updated on 12/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroBo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.